Stockscreener 앱 받기
0.61
0.10%
-0.0006
시간 외 거래:
.61
전일 마감가:
$0.6106
열려 있는:
$0.601
하루 거래량:
26,428
Relative Volume:
0.29
시가총액:
$2.75M
수익:
$7,500
순이익/손실:
$-9.84M
주가수익비율:
-0.1065
EPS:
-5.7263
순현금흐름:
$-9.25M
1주 성능:
+3.04%
1개월 성능:
+3.67%
6개월 성능:
-26.05%
1년 성능:
-86.04%
1일 변동 폭
$0.6001
$0.6275
1주일 범위
$0.5902
$0.63
52주 변동 폭
$0.5038
$4.37
Oragenics Inc Stock (OGEN) Company Profile
명칭
Oragenics Inc
전화
813-286-7900
주소
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.61 | 2.82M | 7,500 | -9.84M | -9.25M | -5.7263 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oragenics Inc 주식(OGEN)의 최신 뉴스
OGEN Q2 2023 Earnings: EPS Beat on Lower-than-Expected Loss, But Stock DeclinesEarnings Forecast Report - newsline.com
OGEN Q2 2023 Earnings: Loss Narrower Than Expected but No Revenue, Stock DeclinesQuarterly Earnings Report - newsline.com
OGEN Q2 2023 Earnings: Narrower Loss Drives 5% Bounce on Surprise BeatRevenue Growth Report - newsline.com
OGEN Q2 2023 Earnings: Smaller-Than-Expected Loss as Clinical Pipeline ProgressesProduct Revenue Analysis - newsline.com
Oragenics Inc. (OGEN) Edges Lower to $0.60, Testing Key Support LevelsEarnings Quality Factor - newsline.com
OGEN Q2 2023 Earnings: EPS Beats Estimates by Over 50% as Company Advances PipelineBanking Earnings Report - newsline.com
OGEN News | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
ORAGENICS INC (OGEN) Stock Chart - ChartMill
Oragenics Inc. (OGEN) Inches Higher as Stock Tests Key Resistance Near $0.64SuperTrend Flip - newsline.com
Oragenics Inc. (OGEN) Slips Amid Low Volume, Hovers Near Key SupportIceberg Order - newsline.com
Oragenics Inc. (OGEN) Edges Higher as Biotech Volatility PersistsIceberg Order - The Legal Advocate
OGEN Q2 2023 Earnings: Narrower-than-Expected Loss Boosts Investor SentimentOpen Signal Network - Newser
OGEN | Oragenics Inc. Executive Compensation - Quiver Quantitative
Oragenics Q2 2023 Earnings: Narrowing Loss Surprises, No Revenue YetFull Year Guidance - Newser
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21 - marketscreener.com
Oragenics (OGEN) Rallies +4.50% as Bulls Target $0.63 2026-05-20Community Buy Signals - Newser
Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference, Highlighting Progress on Concussion Treatment - MEXC
Oragenics Highlights Investor Outreach at Micro-Cap Conference - TipRanks
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21 - Yahoo Finance
Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device - TradingView
ORAGENICS PROVIDES INVESTOR UPDATE - Sahm
Oragenics (OGEN) Q2 2023 Earnings Surprise: EPS $-1.51, Up SignificantBanking Earnings Report - Newser
Oragenics Advances Phase IIa Trial for Concussion Treatment, Eyes CNS Expansion - citybuzz -
Oragenics advances concussion drug trial, signs device LOI - Investing.com UK
Oragenics advances concussion drug trial, signs device LOI By Investing.com - Investing.com Nigeria
OGEN Technical Analysis | Trend, Signals & Chart Patterns | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
TradingKey - TradingKey
Oragenics (OGEN) continues pipeline investments amid losses; CEO discusses strategic priorities and funding outlook.Crowd Entry Points - Newser
Oragenics: Q1 Earnings Snapshot - 10tv.com
Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Oragenics | 10-Q: Q1 2026 Earnings Report - Moomoo
Oragenics Signs LOI to License CardioDialysis Technology for Neurodegenerative Diseases - citybuzz -
Oragenics signs letter of intent to license blood purification tech - Investing.com
Oragenics signs letter of intent to license blood purification tech By Investing.com - Investing.com Australia
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation - ChartMill
Oragenics IncSigns Letter Of Intent To License Cardiodialysis From Sigyn TherapeuticsSEC Filing - TradingView
Oragenics Signs Letter of Intent to License CardioDialysis™ - GlobeNewswire
Oragenics adds second site to concussion drug trial in Australia By Investing.com - Investing.com India
Oragenics Expands Phase IIa Trial for Concussion Treatment to Second Site - MEXC
Oragenics, Inc. Opens Second Clinical Site for Phase IIa Trial of ONP-002, Evaluating Treatment for Concussion with 60 Participants - geneonline.com
Oragenics adds second site to concussion drug trial in Australia - Investing.com
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. - Yahoo Finance
Oragenics shares plunge following announcement of $20 million preferred stock sale - MSN
Oragenics Inc (OGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):